Previous 10 | Next 10 |
FORT MYERS, FL / ACCESSWIRE / October 28, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the " Company " ), a leading provider of cancer-focused genetics testing services and global oncology contract research services, is providing an update on its discussions with MolDX and on its commercial launc...
FT. MYERS, FL / ACCESSWIRE / October 13, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its third quarter 2022, financial results on Tuesday, November 8, 2022. The Co...
Summary NeoGenomics continues to present with heightened downside risk and doesn't warrant inclusion into equity portfolios. NEO shares have been heavily compressed in 2022 as investors unload names with weakening fundamentals. The lack of earnings and return on capital makes ...
Data Supports the Application of RaDaR™ MRD Assay Across Tumor Types Early Research on Potential Biomarker in Melanoma Patients Unresponsive to Immunotherapy FT. MYERS, FL / ACCESSWIRE / September 7, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused...
Needham downgraded NeoGenomics, Inc. ( NASDAQ: NEO ), an operator of cancer-focused testing labs, to Hold from Buy on Monday, arguing that the company's turnaround plan is only an initial step and is likely to take longer to yield meaningful results. The 18-month plan called...
NeoGenomics ( NASDAQ: NEO ) granted its new CEO Chris Smith equity awards. The company said Smith will be granted ~336.77K restricted common stock, a sign-on award of ~265.45K restricted stock common, and a stock option to buy ~694.44K common shares, in each case e...
FT. MYERS, FL / ACCESSWIRE / August 16, 2022 / NeoGenomics, Inc. (Nasdaq:NEO), a leading provider of oncology testing and global contract research services, today announced, as required by the Nasdaq Listing Rules, equity inducement awards to Mr. Chris Smith, the company's new chief executiv...
The following slide deck was published by NeoGenomics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: NeoGenomics, Inc. 2022 Q2 - Results - Earnings Call Presentation
NeoGenomics, Inc. (NEO) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Lynn Tetrault – Interim CEO Charlie Eidson – Director of Investor Relations Bill Bonello – Chief Financial Officer Chris Smith –...
NeoGenomics ( NASDAQ: NEO ) is trading 13.5% higher after the company reported better-than-expected Q2 result, helped by clinical service unit. The company, who's new CEO Chris Smith is all set to take his position on August 15, posted total revenue of $12...
News, Short Squeeze, Breakout and More Instantly...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 ...
2024-06-23 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in...